Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En plattformsprövning för gramnegativa blodomloppsinfektioner (BALANCE+)

5 november 2026 uppdaterad av: Dr. Nick Daneman, Sunnybrook Health Sciences Centre

BALANCE+: En plattformsprövning för gramnegativa blodomloppsinfektioner

BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs). Each domain addresses critical questions in the management of GN BSIs, aiming to refine treatment strategies, enhance patient outcomes, and reduce antimicrobial resistance.

The initial vanguard pilot RCT (NCT05893147) started on 29 August 2023 and has successfully completed the pilot phase on 24-Apr-2024. All patients enrolled in the vanguard phase are part of the main platform trial.

Studieöversikt

Detaljerad beskrivning

BALANCE+ is an adaptive platform trial evaluating multiple treatment options in patients admitted to the hospital due to Gram negative bloodstream infections (BSIs). It focuses on both cross-cutting and subgroup-specific questions, using an open-label, pragmatic design embedded in routine care.

BALANCE+ addresses the significant health concern of BSIs, which have high morbidity and mortality rates, exacerbated by the global public health threat of antimicrobial resistance (AMR). With rising resistance rates and limited new drug development, effective treatment strategies for BSIs remain under-researched.

BALANCE+ follows the BALANCE trial, which evaluated duration of antibiotic treatment, and aims to further investigate critical questions in managing Gram-negative BSIs. This platform trial will explore various aspects of BSI treatment, including antibiotic de-escalation, oral antibiotic choices, central line management, treatment of specific pathogens, and the necessity of follow-up blood cultures.

BALANCE+ is using Bayesian methods without a fixed sample size. Interim analyses will occur after every 1000th patient in each domain, and then for every 200th patient thereafter. The trial will stop if futility or superiority thresholds are met, or if a domain reaches its ceiling sample size (2500 patients for most domains and 4000 for the beta-lactam versus non-beta-lactam domain) without meeting a stopping threshold.

A vanguard pilot trial involving over 150 patients at 9 hospitals across Canada confirmed the feasibility of the BALANCE+ trial. The main trial will include patients from the vanguard pilot phase since there has been no major change in the overall study design and domains. The adaptive design allows for interim analyses and adjustments by adding or removing domains as per the statistical analysis plan, enhancing the trial's efficiency and relevance.

Studietyp

Interventionell

Inskrivning (Beräknad)

2500

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • New South Wales
      • Kogarah, New South Wales, Australien, 2217
        • Rekrytering
        • St George Hospital
        • Huvudutredare:
          • Richard Sullivan
        • Kontakt:
        • Underutredare:
          • Pam Konecny
        • Kontakt:
          • Rachael Roberts, Research Coordinator
      • New Lambton, New South Wales, Australien
        • Rekrytering
        • John Hunter Hospital
        • Kontakt:
        • Kontakt:
          • Telefonnummer: +61 2 4921 3000
        • Huvudutredare:
          • Joshua Davis
    • Queensland
      • Herston, Queensland, Australien, 4006
        • Rekrytering
        • Royal Brisbane and Women's Hospital
        • Kontakt:
        • Huvudutredare:
          • Patrick Harris, Infectious Disease Physician
      • Redcliffe, Queensland, Australien
      • Sunshine Coast, Queensland, Australien
        • Rekrytering
        • Sunshine Coast University Hospital
        • Kontakt:
        • Huvudutredare:
          • Gururaj Nagaraj
    • Victoria
      • Clayton, Victoria, Australien
        • Rekrytering
        • Monash Medical Center
        • Huvudutredare:
          • Ben Rogers
        • Kontakt:
    • Western Australia
      • Murdoch, Western Australia, Australien
        • Rekrytering
        • Fiona Stanley Hospital
        • Kontakt:
        • Huvudutredare:
          • Edward Raby
      • Murdoch, Western Australia, Australien
        • Rekrytering
        • St John of God
        • Kontakt:
        • Huvudutredare:
          • Adrian Regli
    • Cundinamarca
      • Chía, Cundinamarca, Colombia
        • Rekrytering
        • Universidad de La Sabana
        • Kontakt:
        • Huvudutredare:
          • Luis Felipe Reyes Velasco
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel
        • Rekrytering
        • Sheba Medical Center
        • Huvudutredare:
          • Dafna Yahav
        • Kontakt:
    • Alberta
      • Calgary, Alberta, Kanada
      • Calgary, Alberta, Kanada
        • Rekrytering
        • Peter Lougheed Centre
        • Huvudutredare:
          • Ranjani Somayaji
        • Kontakt:
      • Calgary, Alberta, Kanada
        • Rekrytering
        • South Health Campus
        • Huvudutredare:
          • Ranjani Somayaji
        • Kontakt:
      • Calgary, Alberta, Kanada
        • Rekrytering
        • Foothills Hospital
        • Kontakt:
          • Ranjani Somayaji, MD
      • Edmonton, Alberta, Kanada
        • Rekrytering
        • University of Alberta
        • Kontakt:
        • Huvudutredare:
          • Wendy Sligl
    • British Columbia
      • Surrey, British Columbia, Kanada
        • Rekrytering
        • Surrey Memorial Hospital
        • Huvudutredare:
          • Kevin Afra
        • Kontakt:
      • Vancouver, British Columbia, Kanada
        • Rekrytering
        • Vancouver General Hospital
        • Huvudutredare:
          • Jennifer Grant
        • Kontakt:
    • Manitoba
      • Winnipeg, Manitoba, Kanada
        • Rekrytering
        • Health Sciences Centre
        • Kontakt:
        • Huvudutredare:
          • Sylvain Lother
      • Winnipeg, Manitoba, Kanada
        • Rekrytering
        • St. Boniface Hospital
        • Huvudutredare:
          • Terry Wuerz
        • Kontakt:
      • Winnipeg, Manitoba, Kanada
    • New Brunswick
      • Fredericton, New Brunswick, Kanada
        • Rekrytering
        • Dr. Everett Chalmers Regional Hospital
        • Kontakt:
        • Huvudutredare:
          • Rosa Rossana
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Kanada
        • Rekrytering
        • Eastern Regional Health Authority
        • Kontakt:
          • Peter Daley, MD
    • Ontario
      • Mississauga, Ontario, Kanada
        • Rekrytering
        • Trillium Health Partners - Mississauga Hospital
        • Kontakt:
        • Kontakt:
          • Mobina Khurram
        • Huvudutredare:
          • Christopher Graham
      • North York, Ontario, Kanada
        • Rekrytering
        • Humber River Health system
        • Kontakt:
        • Huvudutredare:
          • Ian Brasg
      • North York, Ontario, Kanada
        • Rekrytering
        • North York General Hospital
        • Kontakt:
        • Huvudutredare:
          • Pavani Das
      • Ottawa, Ontario, Kanada
        • Rekrytering
        • The Ottawa Hospital
        • Kontakt:
          • Derek McFadden, MD
      • St. Catharines, Ontario, Kanada
        • Rekrytering
        • Niagara Health System
        • Kontakt:
          • Aidan Findlater, MD
      • Toronto, Ontario, Kanada
        • Rekrytering
        • University Health Network
        • Kontakt:
          • Bryan Coburn, MD
      • Toronto, Ontario, Kanada, M4N3M5
        • Rekrytering
        • Sunnybrook Health Sciences Centre
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Rob A Fowler, MD
        • Huvudutredare:
          • Nick Daneman, MD
      • Toronto, Ontario, Kanada
        • Rekrytering
        • Michael Garron Hospital
        • Kontakt:
          • Christopher Kandel, MD
      • Toronto, Ontario, Kanada
        • Rekrytering
        • Mount Sinai Hospital
        • Kontakt:
          • Michael Fralick, PhD
      • Toronto, Ontario, Kanada
        • Rekrytering
        • St. Joseph's Health Centre
        • Kontakt:
        • Huvudutredare:
          • Kevin Schwartz
    • Quebec
      • Laval, Quebec, Kanada
        • Rekrytering
        • Hôpital de la Cité de la Santé
        • Kontakt:
        • Huvudutredare:
          • Marco Bergevin
        • Underutredare:
          • Stéphanie Castonguay
        • Underutredare:
          • Olivier Haeck
        • Underutredare:
          • Esther Simoneau
        • Underutredare:
          • Marios Roussos
        • Underutredare:
          • Natalie Rivest
        • Underutredare:
          • Tuyen Nguyen
      • Laval, Quebec, Kanada
        • Rekrytering
        • CHU de Québec - Université Laval
        • Kontakt:
        • Huvudutredare:
          • Francois Lauzier
        • Underutredare:
          • Julie Bestman-Smith
      • Montreal, Quebec, Kanada
        • Rekrytering
        • Montreal General Hospital- McGill
        • Kontakt:
        • Huvudutredare:
          • Todd C Lee
        • Huvudutredare:
          • Emily Mcdonald
      • Montreal, Quebec, Kanada
        • Rekrytering
        • Royal Victoria Hospital- McGill
        • Kontakt:
        • Huvudutredare:
          • Emily McDonald
        • Huvudutredare:
          • Todd C Lee
      • Sherbrooke, Quebec, Kanada
        • Rekrytering
        • Université de Sherbrooke
        • Kontakt:
          • François Lamontagne, MD
      • Trois-Rivières, Quebec, Kanada, G8Z 3R9
        • Rekrytering
        • Centre hospitalier affilié universitaire régional (CHAUR)
        • Kontakt:
        • Huvudutredare:
          • Jean-François Naud
    • Auckland
      • Auckland, Auckland, Nya Zeeland, 2025
        • Rekrytering
        • Middlemore Hospital
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Susan Morpeth, Clinical Microbiologist
        • Underutredare:
          • Michael Trent Herdman, Specialist Registrar
      • Takapuna, Auckland, Nya Zeeland, 0622
    • Wellington Region
      • Newtown, Wellington Region, Nya Zeeland, 6021
        • Rekrytering
        • Wellington Hospital
        • Kontakt:
        • Huvudutredare:
          • Maxim Bloomfield
        • Underutredare:
          • Paul Young

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

1 sekund till 130 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

PLATFORM INCLUSION CRITERIA

Platform Inclusion Criteria:

  • admitted to a participating hospital
  • positive blood culture with Gram negative (GN) bacterium

Platform Exclusion Criteria:

  • patient's goals of care are for palliation with no active treatment
  • moribund patient, not expected to survive > 72 hours
  • previously enrolled in the platform trial
  • not eligible for any domain at the time of screening

DOMAIN SPECIFIC INCLUSION AND EXCLUSION CRITERIA

  1. De-escalation versus no de-escalation domain

    Inclusion Criteria

    - included in BALANCE+ platform

    Exclusion Criteria

    • receiving an empiric antibiotic regimen at the time of blood culture finalization to which the GN pathogen(s) are not sensitive

    • arbapenem-non-susceptible

    • no de-escalation option due to any or all of:

      • antimicrobial resistance
      • allergies
      • medical contraindications
      • drug-drug interaction risk
      • other relevant reason
    • patients with a suspected or proven polymicrobial source of infection

    • > 24 hours since index blood culture susceptibility results finalization

  2. Beta-lactam versus non-beta-lactam oral/enteral treatment domain

    Inclusion Criteria

    • included in BALANCE+ platform
    • initially treated with intravenous antibiotics, but clinical team transitioning patient to oral/enteral antibiotic within 7 days of starting treatment

    Exclusion Criteria

    • enrolled in an arm of another BALANCE+ platform domain which limits the use of oral/enteral therapy:

    • no-de-escalation arm (patients in the no de-escalation arm cannot be randomized into this domain unless they are ready for discharge home, in which case de-escalation is allowable to oral agents at discharge)

    • no non-beta-lactam options due to any or all of:

      • resistance
      • allergies
      • medical contraindications
      • drug-interaction risk
      • other relevant reason
    • no beta-lactam options due to any or all of:

      • resistance
      • allergies
      • medical contraindications
      • drug-interaction risk
      • other relevant reason
    • pregnancy

    • already received >24 hours of oral antibiotics after index blood culture finalization

  3. Central vascular catheter replacement domain

    Inclusion Criteria

    • included in BALANCE+ platform
    • has an indwelling central vascular catheter that was already in place within the 48-hour period before the onset of bloodstream infection (i.e. is not a new catheter placed within 48 hours of the onset of infection)

    Exclusion Criteria

    • patient has no ongoing need for a central vascular catheter

    • patient has definite indication for central vascular catheter removal

    • ongoing septic shock with definite/probable line source o concomitant S. aureus bacteremia

      • concomitant candidemia
    • local suppurative signs (severe redness, warmth, pain, swelling or fluctuance/collection) necessitating catheter removal, or other clinical evidence of infected line (e.g. imaging/echocardiographic findings)

  4. Low-risk AmpC domain

    Inclusion Criteria

    • included in BALANCE+ platform
    • positive blood culture with GN bacterium, of the following species: i. Serratia spp. ii Morganella spp. iii Providencia spp. iv Proteus spp. other than P.mirabilis
    • organism is susceptible to ceftriaxone

    Exclusion Criteria

    - severe allergy to beta-lactams (e.g., type 4 hypersensitivity reaction or DRESS)

    • baseline phenotypic non-susceptiblity to ceftriaxone
    • more than 1 calendar day beyond availability of susceptibility results
  5. Follow up blood culture domain

    Inclusion Criteria

    - included in BALANCE+ platform

    Exclusion Criteria

    • patient died or discharged from hospital prior to day 4
    • blood culture already collected by the treating team at day 4±1
    • >5 days since index positive blood culture collection
    • definite indication for repeat blood culture testing o concomitant S. aureus bacteremia o concomitant Candidemia o clinical suspicion for infective endocarditis
  6. 4 day versus 7-day antibiotic duration

    Inclusion Criteria • improving clinical trajectory, based on meeting all of these criteria by the 4th calendar day of adequate antibiotics:

    o temperature 35.0ºC-37.9ºC

    o not on vasopressors

    o FiO2 ≤ 50%

    Exclusion Criteria

    • Has not undergone successful source control (if required) before completing 4th calendar day of adequate antibiotics

    • Neutropenia (<0.5 × 10⁹/L)

    • solid organ or bone marrow transplantation
    • suspected or documented deep-seated infection requiring prolonged antibiotics

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Deeskalering VS Ingen Deeskalering

No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital.

De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol).

Aktiv komparator: Orala betalaktamer VS Orala Icke-beta-laktamer

Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime.

Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.

Aktiv komparator: Central vaskulär kateterretention VS Central vaskulär kateterbyte

Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 3 calendar days from blood culture finalization (removal must happen within that time; replacement can occur after that time point)

Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed.

Aktiv komparator: Cefalosporin VS Carbapenem för AmpC-organismer med låg risk

Cephalosporin (ceftriaxone) at standard doses

Carbapenem (Meropenem or Ertapenem) at standard doses

Aktiv komparator: Routine follow-up blood culture VS No routine follow-up blood culture

Enrollment to the domain has been completed.

Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.

No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria

Aktiv komparator: 4-day versus 7-day antibiotic duration

The shorter duration arm will receive 4 days of adequate antibiotics. The longer duration arm will receive 7 days of adequate antibiotics.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Desirability of Outcome Ranking (DOOR) Ordinal Scale which incorporates death, reinfection, readmission, and for some domains incorporates a tie-breaker of new antimicrobial resistance (AMR).
Tidsram: 90 days

The primary outcome for each domain will use a Desirability of Outcome Ranking (DOOR) ordinal scale in which patients are categorized into the following mutually exclusive categories, ranked from best to worst status:

  1. Alive with no reinfection or readmission.
  2. Alive with reinfection OR readmission.
  3. Alive with reinfection AND readmission.
  4. Dead

For the 4 antibiotic-related domains (the de-escalation versus no de-escalation domain, the beta-lactam versus non-beta-lactam domain, the low risk AmpC domain, and the 4 versus 7 day duration domain) there will be an additional tie-breaker within ordinal levels 1, 2 and 3 based on whether there was new detection of antimicrobial resistance (AMR).

90 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
30 dagars dödlighet
Tidsram: 30 dagar
30 dagar
90 dagars dödlighet
Tidsram: 90 dagar
90 dagar
60 dagars dödlighet
Tidsram: 60 dagar
60 dagar
90 dagar alla orsakar återinläggning
Tidsram: 90 dagar
90 dagar
90-dagars AMR-kolonisering/infektion
Tidsram: 90 dagar
90 dagar
90-dagars Clostridioides difficile-infektion (CDI)
Tidsram: 90 dagar
90 dagar
90 dagars återinfektion
Tidsram: 90 dagar
90 dagar
Additional Secondary Outcomes for Follow up blood culture domain
Tidsram: 90 days
  • total duration of antibiotic therapy
  • hospital length of stay
90 days
Additional Secondary Outcomes for De-escalation versus no de-escalation Domain
Tidsram: 90 days
  • change in total microbiome diversity between the day of randomization and discharge (or day 30 if earlier)
  • net change in resistome AMR burden between the day of randomization and discharge (or day 30 if earlier).
90 days
Additional Secondary Outcomes for Beta-lactam versus non-beta-lactam domain
Tidsram: 90 days
  • antibiotic-related allergic reaction
  • antibiotic-related adverse event
90 days
Additional Secondary Outcomes for Central vascular catheter replacement versus retention domain
Tidsram: 90 days
  • pneumothorax or thoracotomy tube insertion related to vascular catheter
  • clinically important bleeding
  • line associated thrombus
  • persistent bacteremia >5d from initial index culture
  • secondary bloodstream infection with new bacterial or fungal organism
90 days
Additional Secondary Outcomes for Low-risk AmpC domain
Tidsram: 90 days
  • isolation of ESBL producing organism or third generation cephalosporin resistant Gram negative organism
  • isolation of a carbapenem-resistant organism
90 days
Additional domain-specific secondary outcomes in 4-day versus 7-day antibiotic duration
Tidsram: 90 days
  • antibiotic-related allergic reaction

  • antibiotic-related (non-allergic) adverse event (grade 4+ or 3+ with treatment change)

  • microbiome/resistome sub-study

    • change in total microbiome diversity (Shannon diversity index) between the day of randomization and day 30
    • change in total microbiome diversity (Shannon diversity index) between the day of randomization and day 7
    • net change in resistome AMR burden between the day of randomization and day 30
    • change in total microbiome diversity (Shannon diversity index) between the day of randomization and day 7
90 days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Nick Daneman, MD, Sunnybrook Health Sciences Centre
  • Huvudutredare: Rob Fowler, MD, Sunnybrook Health Sciences Centre

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

24 april 2024

Primärt slutförande (Beräknad)

1 april 2027

Avslutad studie (Beräknad)

1 april 2028

Studieregistreringsdatum

Först inskickad

25 juli 2024

Först inskickad som uppfyllde QC-kriterierna

31 juli 2024

Första postat (Faktisk)

5 augusti 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 4369-1

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera